

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Monday, May 14, 2007

<u>Hide?</u>	<u>Set</u>	<u>Name</u>	<u>Query</u>	<u>Hit Count</u>
			<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L8		p185\$ adj (monkey or rhesus or macaca or mulatta)	0
<input type="checkbox"/>	L7		L6 not l4	7
<input type="checkbox"/>	L6		l5 and (l2 or v-erbb2 or mln19)	9
			<i>DB=DWPI,JPAB,EPAB,USPT,PGPB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L5		("CILIBERTO-GENNARO".IN. "NUZZO-MAURIZIO".IN. "NUZZO-M".IN. "MONACI-PAOLO".IN. "MONACI-P".IN. "POMEZIA".IN. "POMEZIA-R".IN.)!	65
			<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L4		(L2 or mln19) adj15 (monkey or rhesus or macaca or mulatta)	7
<input type="checkbox"/>	L3		(L2 or mln19) adj8 (monkey or rhesus or macaca or mulatta)	7
<input type="checkbox"/>	L2		her2 or neu or verb2 or (avian erythroblastic leukemia viral oncogene) or (neuroglioblastoma derived oncogene) or ngl or (cerb b2) or (c-erbb2) or (verb2) or (avian erythroblastic leukemia viral) or tkr1 or (cerb-b2) or herstatin	15852
			<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1		her2 or neu or verb2 or (avian erythroblastic leukemia viral oncogene) or (neuroglioblastoma derived oncogene) or ngl or (cerb b2) or (c-erbb2) or (verb2) or (avian erythroblastic leukemia viral) or tkr1 or (cerb-b2) or herstatin	6754

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 13:44:08 ON 14 MAY 2007)

FILE 'MEDLINE, CAPLUS, EMBASE' ENTERED AT 13:44:30 ON 14 MAY 2007

FILE 'MEDLINE, CAPLUS, EMBASE' ENTERED AT 13:44:44 ON 14 MAY 2007

L1 24928 S 2 HER2 OR NEU OR VERBB2 OR (AVIAN ERYTHROBLASTIC LEUKEMIA VIR
L2 9 S L1 (15A) (MONKEY OR MACACA OR RHESUS OR MULATTA)
L3 5 DUP REM L2 (4 DUPLICATES REMOVED)

=>

Gene Search Result For her2

[Search her2 for species](#)
[Search her2 among product webpages](#)

Human

Mouse

Rat

Others

ERBB2 antibody siRNA ELISA recombinant protein cDNA clone

synonyms: **her2** **neu**; **her2**; **verb2** avian erythroblastic leukemia viral oncogene homolog 2 neuro glioblastoma derived oncogene homolog; **ngl**; **cerb b2**; **verb2** avian erythroblastic leukemia viral oncog; **tkr1**; tyrosine kinase type cell surface receptor; **neu**; **cerb b2** **neu**; **herstatin**; neuroblastoma glioblastoma derived oncogene homolog; neuroblastoma glioblastoma derived oncogene homolo; **v-erb-b2** erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homol

CASC4 antibody siRNA cDNA clone

synonyms: **gene associated with her2 neu overexpression**; **h63**; **dkfzp459f1927**; **mgc74708**; **cancer susceptibility candidate 4**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/061105 A1

(51) International Patent Classification⁷: C12N 15/12,
15/861, 5/16, C07K 14/71, C12P 21/02, A61K 38/17,
48/00

Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT).
LA MONICA, Nicola [IT/IT]; IRBM, Via Pontina Km.
30, 600, I-00040 Pomezia (Rome) (IT). MONACI, Paolo
[IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia
(Rome) (IT). NUZZO, Maurizio [IT/IT]; IRBM, Via Pon-
tina Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(21) International Application Number:
PCT/EP2003/014997

(74) Agent: MAN, Jocelyn; Merck & Co., Inc., European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(22) International Filing Date:
29 December 2003 (29.12.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

(26) Publication Language: English

(30) Priority Data:
60/437,846 3 January 2003 (03.01.2003) US

[Continued on next page]

(71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA [IT/IT]; Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CILIBERTO, Genaro [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT). LAHM, Armin [DE/IT]; IRBM,

(54) Title: RHESUS HER2/NEU, NUCLEOTIDES ENCODING SAME, AND USES THEREOF

Predicted Amino Acid Sequence of First Rhesus
Her2/Neu Protein (SEQ ID NO:2)

1 MELAAWYRNG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVQVQNL
61 ELYLPTNAS LSFQLDIQEV QGYVILAHQV VRQVPLQLRL IVRQGTLFED NYALAVLNG
121 DLLNNNTTPVT GASPGGLREL QLRSLTEILK GGVLJQRNQ LCYQDTILWK DIFHKNNQLA
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESSE DCQSLTRTVC AGGCCAKGP LPTDCCHEQC
241 AAGCTGPKHS DCLACLMFHNS SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTVLCPPLHNO EVAEDGTQK CEKCKSPCAR VCYGLGMEHI REVRAVTSAN
361 IQEFAFGKKI FGSLAFLPES FDGDGPASNTA PLQPEQLRPF ETLEETITGYL YISAWPDSLP
421 DLSVLQNLQV IGRIRLHNGA YSLTLQGLGI SWLGLRSRE LGSSGLALIH NTRLCFVHTV
481 PWDLQFRNPH QALLHTANRP EDECVGEGGLA CHQLCARGHC WGPPTQCVN CSQFLRGQEC
541 VEECRVLQQL PREYVNRARHC LPCHPECQPQ NGSVTCFGPE ADQCVCAHY KOPPFVCAR
601 PSGVKPDLSY MPTWKFDPDEE GTCSQSCPINC THSCVQDLDK GCPAEQRASP LTSIISAVVG
661 ILLVVVLGVV FGILIKRQQ KIRKYTMRLQ LOETELVEPL TPSGAMPQNA QMRILKTEL
721 RKVKVLGSGA FGTVYKGWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
781 YVSRLLGICL TSTVQLVTQI MPYCLLHDV RENRGRLSQ DLLNNCMQIA KGMSYLEDVR
841 LVHRDLAARN VLVKSPNHWK ITDFFGLARLL DIOETEYHAD GGKVIKWM A LESILRRFT
901 HQSDWVSYGV TWELMTFGA KPYQDGPARE IPDLLEKGER LPQPPCTID VYIMVWKCMW
961 IDSECRRPRFR ELVSEFSRMA RDQPRQFVVIQ NEDLGPASPL DSTFYRSLL DDDMGDLVDA
1021 EYELVPOQGF FCPDPAPGTG GMVWHRHSS STRSGGGDLT LGLEPSEEEA PRSPRAPSEG
1081 TGSQVFDGDL GMGAAGLQS LPAHDPSPLQ RYSEOPTVPL PSETQGYVAP LTCSPPEYV
1141 NQPDVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAGGAA VENPEYLAPR
1201 GGAAPQPHLP PAFSPAFDNL YYWQDPDSER GAPPSTFKGT PTAENPEYLG LDVPL*

(57) Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

WO 2004/061105 A1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP03/14997

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/861 C12N5/16 C07K14/71 C12P21/02
A61K38/17 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/14503 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); FOY TERESA M (US); KALOS) 21 February 2002 (2002-02-21) page 3, line 1 -page 6, line 9 page 9, line 14 -page 14, line 10 page 38, line 12 -page 41, line 4 page 56, line 22 -page 83, line 29; example 1 Sequence Listing: SEQ ID NOS: 1 and 2	1-20
Y	WO 02/13847 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); CHEEVER MARTIN A (US); GA) 21 February 2002 (2002-02-21) page 2, line 9 -page 4, line 13 page 6, line 4 -page 17, line 11 page 23, line 15 -page 34, line 3 Sequence Listing: SEQ ID NOS: 1 and 2	1-20 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the International search

27 May 2004

Date of mailing of the International search report

04/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Donath, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/03/14997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 869 445 A (DISIS MARY L ET AL) 9 February 1999 (1999-02-09) column 2, line 25 -column 3, line 12 column 6, line 27 - line 53; example 4 Sequence Listing: SEQ ID NOS: 1 and 2	1-20
A	FENDLY B M ET AL: "SUCCESSFUL IMMUNIZATION OF RHESUS MONKEYS WITH THE EXTRACELLULAR DOMAIN OF P185HER2: A POTENTIAL APPROACH TO HUMAN BREAST CANCER" VACCINE RESEARCH, MARY ANN LIEBERT, INC., PUBLISHERS, US, vol. 2, no. 3, 1993, pages 129-139, XP009030428 abstract	1-20
A	DISIS M L ET AL: "HER-2/NEU PROTEIN: A TARGET FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY OF HUMAN CANCER" ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 71, 1991, pages 343-371, XP000982776 ISSN: 0065-230X the whole document	1-20
A	HUNG M-C ET AL: "HER-2/NEU-TARGETING GENE THERAPY - A REVIEW" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 159, no. 2, 1995, pages 65-71, XP002057855 ISSN: 0378-1119 the whole document	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/14997

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8-11 and 14-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

L4: Entry 2 of 7

File: PGPB

Oct 12, 2006

PGPUB-DOCUMENT-NUMBER: 20060228335

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060228335 A1

TITLE: Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof

PUBLICATION-DATE: October 12, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Aurisicchio; Luigi	Rahway	NJ	US
Palombo; Fabio	Rome		IT
Monaci; Paolo	Roma		IT
La Monica; Nicola	Rome		IT
Ciliberto; Gennaro	Rome		IT
Lahm; Armin	Rome		IT

APPL-NO: 10/545515 [PALM]

DATE FILED: February 9, 2004

RELATED-US-APPL-DATA:

us-provisional-application US 60447203 20030213

PCT-DATA:

DATE-FILED	APPL-NO	PUB-NO	PUB-DATE	371-DATE
Feb 9, 2004	PCT/EP04/01181			Aug 15, 2005

INT-CL-PUBLISHED:

TYPE	IPC	DATE	IPC-OLD
IPCP	A61K48/00	20060101	A61K048/00
IPCS	C07H21/04	20060101	C07H021/04
IPCS	C12P21/06	20060101	C12P021/06
IPCS	C07K14/82	20060101	C07K014/82
IPCS	C12N5/06	20060101	C12N005/06

INT-CL-CURRENT:

TYPE	IPC	DATE
CIPP	<u>A61 K 48/00</u>	20060101
CIPS	<u>C07 H 21/04</u>	20060101
CIPS	<u>C07 K 14/82</u>	20060101
CIPS	<u>C12 N 5/06</u>	20060101
CIPS	<u>C12 P 21/06</u>	20060101

US-CL-PUBLISHED: 424/093.2; 514/044, 435/069.1, 435/320.1, 435/362, 530/350, 536/023.5

US-CL-CURRENT: 424/93.2; 435/320.1, 435/362, 435/69.1, 514/44, 530/350, 536/23.5

ABSTRACT:

DNAs encoding rhesus monkey carcinoembryonic antigen (rhCEA) have been isolated, cloned and sequenced. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhCEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)[Generate Collection](#)[Print](#)[Search Forms](#)[Search](#)[Results](#)[User Searches](#)

14. Entry 2 of 7

[Preferences](#)

File: PGPB

Oct 12, 2006

[Logout](#)

DOCUMENT-IDENTIFIER: US 20060228335 A1

TITLE: Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof

Description of Disclosure:

[0129] The same group of animals was boosted by injection of a mixture of three Ad5-expressing rhesus CEA (Ad5-rhCEA), rhesus HER2/neu (Ad5-rhHER2), and rhesus EpCAM (Ad5-rhEpCAM). A total amount of 3.times.10exp11 viral particles (vp), were injected i.m. at weeks 23 and 27 (1.times.10exp11 vp for each of the three viruses).

Description of Disclosure:

[0133] The cell mediated response was measured by IFN. gamma. ELISPOT assay. For Her2/Neu, three out of four monkeys showed a detectable response. No significant cell mediated responses were measured for rhCEA and rhEpCAM.

Description of Disclosure:

[0134] In summary, the immunization protocol discussed above was effective in inducing a specific immune response against rhHER2/neu in rhesus monkeys. It is unclear why co-immunization with vectors carrying three different tumour antigens was not effective in inducing an immune response against rhCEA, as compared to study 1, which used only rhCEA as immunogen. Though not wishing to be bound by theory, it is possible that the expression of rhHER2/Neu and the presence of immunodominant epitopes limited the generation and the expansion of subdominant rhCEA specific T-cells.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

<!--StartFragment--> Query Match 99.6%; Score 6777; DB 8; Length 1255;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 1250; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy **Av0: 41** 1 MELAAWYRWGLLALLPPGAAGTQVCTGTDMLRLPASPETHLDMLRHLYQGCQVVQGNL 60
Db **Av0: 2** 1 MELAAWYRWGLLALLPPGAAGTQVCTGTDMLRLPASPETHLDMLRHLYQGCQVVQGNL 60

Qy 61 ELTYLPTNASLSFLQDIQEVGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG 120
Db 61 ELTYLPTNASLSFLQDIQEVGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG 120

Qy 121 DLLNNTPVTGASPGLRELQLRSLTEILKGGVLIQRNPQLCYQDTIILWKDIFHKNNQLA 180
Db 121 DPLNNTPVTGASPGLRELQLRSLTEILKGGVLIQRNPQLCYQDTIILWKDIFHKNNQLA 180

Qy 181 LTLIDTNRSRACHPCSPVCKGSRCWGESSEDQSLTRVCAGGCARCKGPLTDCCHEQC 240
Db 181 LTLIDTNRSRACHPCSPVCKGSRCWGESSEDQSLTRVCAGGCARCKGPLTDCCHEQC 240

Qy 241 AAGCTGPKHSDCLACLFNHSGICELHCPALVTYNTDTFESMPNPEGRTFGASCVTACP 300
Db 241 AAGCTGPKHSDCLACLFNHSGICELHCPALVTYNTDTFESMPNPEGRTFGASCVTACP 300

Qy 301 YNYLSTDVGSC TLVCP LHNQEVTAEDGTQRCEKSKPCARV CYGLGMEHLREVRAVTSAN 360
Db 301 YNYLSTDVGSC TLVCP LHNQEVTAEDGTQRCEKSKPCARV CYGLGMEHLREVRAVTSAN 360

Qy 361 IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLRVFETLEEITGYLYISAWPDSLP 420
Db 361 IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLRVFETLEEITGYLYISAWPDSLP 420

Qy 421 DLSVLQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHNNTRLCFVHTV 480
Db 421 DLSVLQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHNNTRLCFVHTV 480

Qy 481 PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGP GPTQCVNC SQFLRGQEC 540
Db 481 PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCAXGH C WGP GPTQCVNC SQFLRGQEC 540

Qy 541 VEECRV LQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC 600
Db 541 VEECRV LQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC 600

Qy 601 PSGVKPDLSYMPIWKFPDEEGTCQSCP INCTHSCVDLDDKGCPAEQRASPLTSIISAVVG 660
Db 601 PSGVKPDLSYMPIWKFPDEEGTCQPCP INCTHSCVDLDDKGCPAEQXASPLTSIISAVVG 660

Qy 661 ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRLKETEL 720
Db 661 ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRLKETEL 720

Qy 721 RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP 780
Db 721 RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP 780

Qy 781 YVSRLLGICLTSTVQLTQLMPYGC LLDHVREN RGR LGSQ DLLNWC M QIAKGMSYLEDVR 840
Db 781 YVSRLLGICLTSTVQLTQLMPYGC LLDHVREN RGR LGSQ DLLNWC M QIAKGMSYLEDVR 840

Qy 841 LVHRDLAARNVLVKSPN HVK ITDFGLARLLDIDETEYHADGGK VPIK WMALESILRRRFT 900
Db 841 LVHRDLAARNVLVKSPN HVK ITDFGLARLLDIDETEYHADGGK VPIK WMALESILRRRFT 900

Qy 901 HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPIC TIDVY MIMVKCWM 960
Db 901 HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPIC TIDVY MIMVKCWM 960

Qy 961 IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA 1020
|||
Db 961 IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA 1020

Qy 1021 EEYLVPQQGFFCPDPAPGTGGMVHHHRRSSSTRSGGDLTLGLEPSEEAPRSRAPSEG 1080
|||
Db 1021 EEYLVPQQGFFCPDPAPGTGGMVHHHRRSSSTRSGGDLTLGLEPSEEAPRSPXAPSEG 1080

Qy 1081 TGSDVFDGDLGMGAAKGLQSLPAHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV 1140
|||
Db 1081 TGSDVFDGDLGMGAAKGLQSLPAHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV 1140

Qy 1141 NQPDVRPQPPSPQEGPLSPARPTGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLAPR 1200
|||
Db 1141 NQPDVRPQPPSPQEGPLSPARPTGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLAPR 1200

Qy 1201 GGAAPQPHLPPAFSPAFDNLYYWDQDPSERGAPPSTFKGPTAENPEYLGDPV 1255
|||
Db 1201 GGAAPQPHLPPAFSPAFDNLYYWDQDPSERGAPPSTFKGPTAENPEYLGDPV 1255

<!--EndFragment-->